Perrigo Company plc Payments to Acquire Equity Method Investments
Perrigo Company plc (PRGO) reported Payments to Acquire Equity Method Investments of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2023-02-28
- Perrigo Company plc payments to acquire equity method investments for the quarter ending 2021-12-31 was $0.00.
- Perrigo Company plc payments to acquire equity method investments for the quarter ending 2021-10-02 was $0.00.
- Perrigo Company plc payments to acquire equity method investments for the quarter ending 2020-12-31 was $0.00.
- Perrigo Company plc payments to acquire equity method investments for the quarter ending 2020-09-26 was $0.00.
- Perrigo Company plc payments to acquire equity method investments for fiscal 2022 was $0.00.
- Perrigo Company plc payments to acquire equity method investments for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Perrigo Company plc payments to acquire equity method investments for fiscal 2020 was $15.00M.
- Perrigo Company plc payments to acquire equity method investments for fiscal 2019 was $0.00.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2021-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2021-07-03 | $0.00 10-Q · filed 2021-08-11 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $15.00M 10-K · filed 2023-02-28 | |
| 2020-09-26 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $15.00M 10-Q · filed 2021-11-12 | ||
| 2020-06-27 | $15.00M 10-Q · filed 2021-08-11 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 | |
| 2019-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-06-29 | $0.00 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |